Clinical Trial Update: AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of cediranib (AZD2171) with fulvestrant in patients with advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-11-28